Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Schistosomiasis vaccines.

Paul Hagan1, Osama Sharaf

  • 1Division of Infection and Immunity, Joseph Black Building (B4-09d), Institute of Biomedical and Life Sciences, University of Glasgow, G12 8QQ UK. P.Hagan@bio.gla.ac.uk

Expert Opinion on Biological Therapy
|December 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

JAG consensus statements for training and certification in colonoscopy.

Frontline gastroenterology·2023
Same author

JAG consensus statements for training and certification in flexible sigmoidoscopy.

Frontline gastroenterology·2023
Same author

Review of 2022 WHO guidelines on the control and elimination of schistosomiasis.

The Lancet. Infectious diseases·2022
Same author

Impact of a national basic skills in colonoscopy course on trainee performance: An interrupted time series analysis.

World journal of gastroenterology·2020
Same author

THE EFFECTS OF MIRAZID FRACTIONS ON THE VIABILITY OF SCHISTOSOMULA OF:SCHISTOSOMA MANSONI: AN IN VITRO STUDY.

Journal of the Egyptian Society of Parasitology·2018
Same author

The feasibility and effectiveness of Catch It, an innovative CBT smartphone app.

BJPsych open·2016

Developing vaccines against schistosomes, the parasitic worms causing schistosomiasis, faces significant hurdles. Despite research advancements, the vaccine effort is stalled, with chemotherapy currently prioritized over schistosomiasis vaccines.

Area of Science:

  • Parasitology
  • Vaccinology
  • Tropical Medicine

Background:

  • Schistosomiasis, caused by parasitic worms called schistosomes, presents major challenges for vaccine development.
  • Previous optimism from animal model vaccine candidates has not translated into successful human clinical trials (Phase III).
  • Current control strategies heavily favor chemotherapy, specifically praziquantel, over vaccine development.

Purpose of the Study:

  • To review the challenges and current status of vaccine development for schistosomiasis.
  • To discuss the stalled progress and the shift towards chemotherapy.
  • To consider the future potential of schistosome vaccine development in light of new genomic and proteomic data.

Main Methods:

  • Review of existing literature on schistosome vaccine candidates and clinical trial progress.

Related Experiment Videos

  • Analysis of the impact of improved understanding of parasite biology and host immune responses.
  • Consideration of the role of advanced schistosome genome projects and proteomics.

    • Main Results:

    • No schistosome vaccine candidate antigens have reached Phase III clinical trials despite initial promise.
    • The field is experiencing a stall in vaccine development efforts.
    • Disagreements exist regarding the necessity of vaccines versus continued reliance on chemotherapy.

    Conclusions:

    • The development of effective schistosome vaccines remains a significant challenge.
    • The current emphasis on chemotherapy may overshadow potential vaccine advancements.
    • Ongoing genomic and proteomic research suggests it may be premature to abandon schistosome vaccine development.